title: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials.
abstract: Clinical trials have shown the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in delaying the progression of diabetic renal disease. There is less evidence from primary clinical trials of nondiabetic renal disease. We performed an updated meta-analysis to determine the efficacy of ACE inhibitors in slowing the progression of renal disease over a broad range of functional renal impairment. We included published and unpublished randomized, placebo-controlled, parallel trials with at least 1 year of follow-up available from January 1970 to June 1999. In nine trials of subjects with diabetic nephropathy and microalbuminuria, the relative risk for developing macroalbuminuria was 0.35 (95% confidence interval [CI], 0.24 to 0.53) for individuals treated with an ACE inhibitor compared with placebo. In seven trials of subjects with overt proteinuria and renal insufficiency from a variety of causes (30% diabetes, 70% nondiabetes), the relative risk for doubling of serum creatinine concentration or developing end-stage renal disease was 0.60 (95% CI, 0.49 to 0.73) for individuals treated with an ACE inhibitor compared with placebo. Treatment of individuals with chronic renal insufficiency with ACE inhibitors delays the progression of disease compared with placebo across a spectrum of disease causes and renal dysfunction.
authors.affiliation: Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, 27599-7155, USA.
authors.forename: A V
authors.initials: AV
authors.lastname: Kshirsagar
authors.forename: M S
authors.initials: MS
authors.lastname: Joy
authors.forename: S L
authors.initials: SL
authors.lastname: Hogan
authors.forename: R J
authors.initials: RJ
authors.lastname: Falk
authors.forename: R E
authors.initials: RE
authors.lastname: Colindres
mesh_terms: D000419:Albuminuria / Q000517:prevention & control; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D011507:Proteinuria / Q000188:drug therapy
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003404:Creatinine